Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 19/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 9/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29392500 | 0.90 | KCNH2 (1.00) | METKCNH2 | |
| SCHEMBL27924860 | 0.90 | MET (1.00) | METKCNH2 | |
| SCHEMBL27804767 | 0.76 | MET (0.61) | METKCNH2 | |
| SCHEMBL19249224 | 0.72 | TDO2 (1.00) | MET | |
| SCHEMBL28790389 | 0.68 | MET (0.66) | METKCNH2 | |
| SCHEMBL27804765 | 0.68 | MET (0.66) | METKCNH2 | |
| SCHEMBL26018140 | 0.68 | MET (0.56) | METKCNH2 | |
| SCHEMBL2640419 | 0.67 | JAK2 (1.00) | METKCNH2 | |
| SCHEMBL520696 | 0.66 | BRD4 (0.55) | METKCNH2 | |
| SCHEMBL17205279 | 0.66 | EGFR (0.72) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230398146-A1 | IMMUNE MODULATION OF MYELOID DERIVED SUPPRESSIVE CELL FUNCTION FOR CANCER TREATMENT | SURGE Therapeutics, Inc. | 2023-12-14 | — | — | US | disclosed |
| CN-116322702-A | Immunomodulation of myeloid-derived suppressor cell function for cancer treatment | 萨吉治疗公司 | 2023-06-23 | — | — | CN | disclosed |
| EP-4196122-A1 | IMMUNE MODULATION OF MYELOID DERIVED SUPPRESSIVE CELL FUNCTION FOR CANCER TREATMENT | Surge Therapeutics, Inc. (US) | 2023-06-21 | — | — | EP | disclosed |
| WO-2022040246-A1 | IMMUNE MODULATION OF MYELOID DERIVED SUPPRESSIVE CELL FUNCTION FOR CANCER TREATMENT | STIMIT CORPORATION (US) | 2022-02-24 | — | — | WO | disclosed |